Full Press Release Details
PSYENCE BIOMEDICAL LTD.
NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS AND
MANAGEMENT INFORMATION CIRCULAR
IN RESPECT OF THE ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS OF PSYENCE BIOMEDICAL LTD. TO BE HELD ON JANUARY 22, 2026
Dated as of January 2, 2026
Neither the NASDAQ nor any securities commission has in any way passed upon the merits of the shareholder proposals described herein and any representation to the contrary is an offence.
The directors of Psyence Biomedical Ltd. ( Psyence, the Company, we, us, or our ) cordially invite you to attend the annual and special meeting (the Meeting ) of the shareholders of Psyence (the Shareholders ) to be held in person at Venture Workspace Riverlands, Office Building 4, Riverlands, 51 Gogosoa Street, Observatory, Cape Town, 7935, on Thursday, January 22, 2026 at 9:00 a.m. (New York time).
At the Meeting, you will be asked to consider and, if deemed appropriate, to pass, the following:
1. to receive and consider the audited financial statements of the Corporation for the year ended March 31, 2025 and interim condensed financial statements for the six months ended September 30, 2025, together with the report of the auditors thereon;
2. the appointment of MNP LLP as the auditor of the Corporation and to authorize the directors to fix their remuneration;
3. the election of directors of the Corporation; and
4. a special resolution approving the proposed consolidation(s) of the common shares of the Corporation;
The foregoing resolutions are referred to herein as the Resolutions .
The Board of Directors of the Corporation unanimously recommends that Shareholders vote in favor of the Resolutions at the Meeting for the reasons set out in this Circular. You are urged to read this information carefully and, if you require assistance, to consult your own legal, tax, financial or other professional advisor.
We hope that we will have the opportunity to welcome you to this year's Meeting.
| Sincerely, | ||
| /s/ Jody Aufrichtig | ||
| Jody Aufrichtig Chief Executive Officer & Director |
NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS
NOTICE IS HEREBY GIVEN that an annual and special meeting (the Meeting ) of the shareholders ( Shareholders ) of Psyence Biomedical Ltd. ( Psyence, the Company, we, us, or our ) to be held in person at Venture Workspace Riverlands, Office Building 4, Riverlands, 51 Gogosoa Street, Observatory, Cape Town, 7935, on Thursday, January 22, 2026 at 9:00 a.m. (New York time) for the following purposes:
1. to receive and consider the audited financial statements of the Corporation as at and for the year ended March 31, 2025 and the interim condensed financial statements for the six months ended September 30, 2025, together with the report of the auditors thereon;
2. the appointment of MNP LLP as the auditor of the Corporation and to authorize the directors to fix their remuneration;
3. the election of directors of the Corporation;
4. a special resolution approving the proposed consolidation(s) of the common shares of the Corporation; and
5. to transact such other business as may properly come before the Meeting.
The specific details of the matters proposed to be put before the Meeting are set forth in the Circular, which accompanies this Notice of Meeting and forms part hereof.
A shareholder wishing to be represented by proxy at the Meeting or any adjournment thereof must have deposited his, her or its duly executed form of proxy not later than 11:59 P.M. (New York time) on Wednesday, January 21, 2026 or, if the Meeting is adjourned, not later than 48 hours, excluding Saturdays, Sundays and holidays, preceding the time of such adjourned Meeting, (1) at the offices of Continental Stock Transfer & Trust Company, 1 State Street, 30th Floor, New York, NY 10004; (2) by calling, toll free at +1 (800) 509-5586 (3) by facsimile at +1 (212) 509-5152; (4) via email to proxy@continentalstock.com; or (5) via internet at www.cstproxyvote.com in accordance with the instructions set out in the proxy card provided to you.
The participation of its shareholders is very important to Psyence. Please ensure that the votes attached to your common shares will be exercised at the Meeting.
DATED at Toronto, Ontario as of the 2nd day of January 2026.
BY ORDER OF THE BOARD OF DIRECTORS
| /s/ Jody Aufrichtig | ||
| Jody Aufrichtig Chief Executive Officer & Director |
MANAGEMENT INFORMATION CIRCULAR
ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS
Dated January 2, 2026, except where otherwise noted
Solicitation of Proxies
This management information circular (the Circular ) is furnished in connection with the solicitation of proxies by the management of Psyence Biomedical Ltd. ( Psyence, the Corporation, we, us, or our ) for use at the annual and special meeting (the Meeting ) of shareholders (the Shareholders ) to be held on Thursday, January 22, 2026 at Venture Workspace Riverlands, Office Building 4, Riverlands, 51 Gogosoa Street, Observatory, Cape Town, 7935 at 9:00 a.m. (New York time), and at any adjournment(s) thereof. Solicitation of proxies will be primarily by mail and by our proxy solicitor Advantage Proxy, but may also be carried out by directors, officers, employees or agents of the Corporation personally, in writing, by telephone or by fax. All cost thereof will be borne by the Corporation. Management of the Corporation has therefore prepared this Circular and has sent it to those shareholders who are entitled to receive a notice of meeting.
Shareholders Entitled to Vote
Registered shareholders ( Registered Shareholders ) as at the close of business on December 23, 2025 (the Record Date ), or the person or persons they appoint as their proxies, are entitled to attend and vote on all matters that may properly come before the Meeting in respect of which their vote is required. Each Shareholder of record at the close of business on the Record Date will be entitled to one vote for each common share of the Corporation, no par value ( Common Share ) held with respect to all matters proposed to come before the Meeting, or any adjournment or postponement thereof, and requiring a vote by Shareholders.
Registered Shareholders are entitled to vote at the Meeting, or any adjournment or postponement thereof, either in person or by proxy. Voting by proxy means that you are giving the person or persons named on your proxy form (your proxyholder) the authority to vote your Common Shares for you at the Meeting or any adjournment(s) or postponement(s) thereof.
Appointment of Proxies and Revocation of Proxies
The individuals named in the enclosed form of proxy will represent management of the Corporation at the Meeting. A Shareholder has the right to appoint a person or company (who need not be a Shareholder), other than the persons designated in the accompanying form of proxy, to represent the Shareholder at the Meeting. Such right may be exercised by inserting the name of such person or company in the blank space provided in the proxy or by completing another proper form of proxy. A Shareholder wishing to be represented by proxy at the Meeting or any adjournment thereof must, in all cases, deposit the completed proxy with Continental Stock Transfer and Trust, 1 State Street 30th Floor, New York, NY 10004 ( CST ) by 10:00 a.m. (New York time) on Wednesday, January 21, 2026 or, if the Meeting is adjourned or postponed, at least 48 hours, excluding Saturdays, Sundays and holidays, prior to any adjournment or postponement of the Meeting at which the proxy is to be used, or deliver it to the Chairman of the Meeting on the day of the Meeting or any adjournment thereof prior to the commencement of the Meeting. A proxy should be executed by the registered Shareholder or its attorney-in-fact duly authorized in writing or, if the registered Shareholder is a corporation, by an officer or attorney thereof duly authorized. Failure to properly complete or deposit a proxy may result in its invalidation.
A Registered Shareholder who has submitted a proxy may revoke it at any time prior to the exercise thereof. If a Registered Shareholder who has given a proxy attends the Meeting in person at which such proxy is to be voted, such person may revoke the proxy and vote in person. In addition to any other manner permitted by law, a proxy may be revoked before it is exercised by an instrument in writing executed in the same manner as a proxy and deposited to the attention of the Chief Financial Officer of the Corporation at the registered office of the Corporation at any time up to and including the last business day preceding the day of the Meeting, or any adjournment thereof, at which the proxy is to be used or with the Chairman of the Meeting on the day of such Meeting or any adjournment thereof and thereupon the proxy is revoked.
A Registered Shareholder attending the Meeting has the right to vote in person and, if he or she does so, his or her proxy is nullified with respect to the matters such person votes upon and any subsequent matters thereafter to be voted upon at the Meeting or any adjournment thereof.
If you are not a Registered Shareholder, please refer to the section below entitled Advice to Beneficial Holders of Common Shares .
Advice to Beneficial Shareholders of Common Shares
The information set forth in this section is of significant importance to many Shareholders as a substantial number of Shareholders do not hold their Common Shares in their own name and thus are considered non-registered Shareholders (referred to as Beneficial Shareholders ). Beneficial Shareholders should note that only proxies deposited by Shareholders whose names appear on the records of the Corporation as the registered holders of Common Shares can be recognized and acted upon at the Meeting. If Common Shares are listed in an account statement provided to Shareholders by a broker then, in almost all cases, those shares will not be registered in the Shareholder's name on the records of the Corporation. Such Common Shares will more likely be registered under the name of the Shareholder's broker or an agent of that broker or another similar entity (an Intermediary ). Common Shares held in the name of an Intermediary can only be voted by the Intermediary (for or against resolutions or withheld) upon the instructions of the Beneficial Shareholder. Without specific instructions, Intermediaries are prohibited from voting shares.
If you are a Beneficial Shareholder:
Beneficial Shareholders should ensure that instructions respecting the voting of their Common Shares are communicated in a timely manner and in accordance with the instructions provided by their Intermediary. Applicable regulatory rules require Intermediaries to seek voting instructions from Beneficial Shareholders in advance of the Meeting. Every Intermediary has its own mailing procedures and provides its own return instructions to clients, which instructions should be carefully followed by Beneficial Shareholders in order to ensure that their Common Shares are voted at the Meeting.
Most brokers now delegate responsibility for obtaining instructions from clients to Broadridge Financial Solutions, Inc. ( Broadridge ) in the United States and in Canada. Broadridge mails a voting instruction form in lieu of a form of proxy provided by the Corporation. The voting instruction form will name the same persons as the Corporation's form of proxy to represent you at the Meeting. You have the right to appoint a person (who need not be a shareholder of the Corporation), other than the persons designated in the voting instruction form, to represent you at the Meeting. To exercise this right, you should insert the name of the desired representative in the blank space provided in the voting instruction form. The completed voting instruction form must then be returned to Broadridge by mail or facsimile or given to Broadridge by phone or over the internet, in accordance with Broadridge's instructions. Broadridge then tabulates the results of all instructions received and provides appropriate instructions respecting the voting of Common Shares to be represented at the Meeting. If you receive a voting instruction form from Broadridge, you cannot use it to vote Common Shares directly at the Meeting the voting instruction form must be completed and returned to Broadridge, in accordance with its instructions, well in advance of the Meeting in order to have the Common Shares voted.
Although a Beneficial Shareholder may not be recognized directly at the Meeting for the purpose of voting Common Shares registered in the name of their Intermediary, a Beneficial Shareholder may attend at the Meeting as proxyholder for the Intermediary and vote the Common Shares in that capacity. Beneficial Shareholders who wish to attend the Meeting and indirectly vote their Common Shares as a proxyholder should enter their own names in the blank space on the form of proxy provided to them by their Intermediary and return the same to their Intermediary in accordance with the instructions provided by their Intermediary well in advance of the Meeting.
Non-registered holders who have not objected to their Intermediary disclosing certain ownership information about themselves to the Corporation are referred to as non-objecting beneficial owners . Those non-registered holders who have objected to their Intermediary disclosing ownership information about themselves to the Corporation are referred to as objecting beneficial owners ( OBOs ).
This Circular and applicable proxy-related materials are being sent directly to non-objecting beneficial owners.
The Corporation does not intend to pay for Intermediaries to deliver the Meeting materials. As a result, OBOs will not receive the Meeting materials unless their Intermediary assumes the costs of delivery.
Interest of Certain Persons or Companies in Matters to Be Acted Upon
Other than as described herein, the Corporation is not aware of: (i) any person who has been a director or executive officer of the Corporation at any time since the beginning of the last financial year; (ii) a nominee for election as a director of the Corporation at the Meeting; or (iii) any associate or affiliate of any such director or executive officer or nominee, who has any material interest, direct or indirect, by way of beneficial ownership of securities or otherwise, in any matter to be acted upon at the Meeting.
Use of Discretionary Power Conferred By the Proxies
Common Shares represented by proxies in favor of management nominees will be voted in accordance with the instructions of the Shareholder on any ballot that may be called for and, if a Shareholder specifies a choice with respect to any matter to be acted upon at the Meeting, the shares represented by proxy shall be voted accordingly. Where no choice is specified, the proxy will confer discretionary authority and will be voted FOR all matters proposed by management at the Meeting. The enclosed form of proxy also confers discretionary authority upon the persons named therein to vote with respect to any amendments or variations to the matters identified in the notice with respect to this Meeting and with respect to any other matters which may properly come before the Meeting in such manner as the nominee in his judgment may determine. At the date hereof, management of the Corporation knows of no such amendments, variations or other matters to come before the Meeting.
Voting Securities and Principal Holders of Voting Securities
The authorized share capital of the Corporation consists of an unlimited number of Common Shares without par value. As at the date hereof, 6,388,604 Common Shares without par value are issued and outstanding. Each Common Share carries the right to one vote at any ballot taken at any meeting of the shareholders. Only shareholders of record of the Corporation at the close of business on the Record Date or their duly authorized agents are entitled to attend and vote at the Meeting.
The following table sets forth information regarding the beneficial ownership of Common Shares on the date of this Circular, based on information obtained from the persons named below, by:
- each person known by Psyence to be the beneficial owner of more than 5% of the outstanding Common Shares;
- each of Psyence's executive officers and directors; and
- all of Psyence's executive officers and directors as a group.
Unless otherwise indicated, Psyence believes that all persons named in the tables below have sole voting and investment power with respect to all shares beneficially owned by them. Except as otherwise noted herein, the number and percentage of Common Shares beneficially owned is determined in accordance with Rule 13d-3 of the Exchange Act, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rule, beneficial ownership includes any Common Shares as to which the holder has sole or shared voting power or investment power and also any Common Shares which the holder has the right to acquire within 60 days of the date of this Circular through the exercise of any option, warrant, convertible security or other right.
| Name of Beneficial Owner (1) | Number of Company Common Shares | % of Company Common Shares | ||
| 5% Holders | ||||
| Directors and Executive Officers | ||||
| Dr. Neil Maresky (2) | 1,723 | * | ||
| Warwick Corden-Lloyd | 568 | * | ||
| Jody Aufrichtig | 1,106 | * | ||
| Marc Balkin | 324 | * | ||
| Christopher (Chris) Bull (3) | 6,947 | * | ||
| Dr. Seth Feuerstein | 116 | * | ||
| Graham Mark Patrick (4) | ||||
| All Directors and Executive Officers as a group (seven individuals) |
(1) Unless otherwise noted, the business address of each of those listed in the table above is 121 Richmond Street West, Penthouse Suite 1300, Toronto, Ontario M5H 2K1.
(2) Dr Neil Maresky resigned as director effective September 19, 2025, and Chief Executive Officer effective October 15, 2025.
(3) Christopher (Chris) Bull resigned as director effective December 1, 2025.
(4) Graham Mark Patrick was appointed as a director effective December 1, 2025.
(5) * Share ownership is below 1%
Background The Business Combination
On January 25, 2024 (the Closing Date ), the Corporation consummated the transactions contemplated by that certain Amended and Restated Business Combination Agreement, dated as of July 31, 2023 (as amended, the Business Combination Agreement and the transactions contemplated thereby, the Business Combination ), by and among the Corporation, Newcourt Acquisition Corp. ( NCAC ), Newcourt SPAC Sponsor LLC (the Sponsor ), Psyence Group Inc., a corporation organized under the laws of Ontario, Canada ( PGI ), Psyence (Cayman) Merger Sub, a Cayman Islands exempted company and a direct and wholly owned subsidiary of the Company ( Merger Sub ), Psyence Biomed Corp., a corporation organized under the laws of British Columbia, Canada ( Psyence Biomed Corp. ), and Psyence Biomed II Corp. ( Biomed II ). Pursuant to the Business Combination, at the effective time of the merger (the Effective Time ) (i) PGI contributed Biomed II to the Corporation in a share for share exchange (the Company Exchange ), (ii) following the Company Exchange, Merger Sub merged with and into NCAC (the Merger ), with NCAC being the surviving company in the Merger, and each outstanding ordinary share of NCAC was converted into the right to receive one Common Share of the Corporation, and (iii) each outstanding warrant to purchase NCAC Class A Ordinary Shares was converted into a warrant to acquire one Common Share on substantially the same terms as were in effect immediately prior to the Closing Date under their terms.
All references to dollars or $ are in U.S. dollars unless otherwise noted.
PARTICULARS OF MATTERS TO BE ACTED UPON
Financial Statements
The shareholders will receive and consider the audited financial statements of the Corporation for the years ended March 31, 2025 and 2024, together with the auditor's report hereon. The shareholders will also receive and consider the interim reviewed condensed financial statements of the Corporation for the six month period ended September 30, 2025.
Appointment of Auditors
Management recommends the appointment of MNP LLP, Chartered Accountants ( MNP ), of Toronto, Ontario, as the auditor of the Corporation to hold office until the close of the next annual meeting of the Shareholders, or until their successor is appointed by the Board. MNP was appointed as the auditor of the Corporation on March 18, 2024, to replace the previous auditor of NCAC, Citrin Cooperman & Company, LLP.
Common Shares represented by proxies in favor of the management nominees will be voted FOR the appointment of MNP LLP, Chartered Accountants, as the auditor of the Corporation and authorizing the directors of the Corporation to fix their remuneration, unless a Shareholder has specified in his proxy that his Common Shares are to be withheld from voting on the appointment of the auditor.
Audit and Non-Audit Fees
The following table sets forth the aggregate fees billed by MNP LLP (the Auditor ) for professional services rendered for the audit of the Corporation's annual financial statements and for other services provided by the Auditor to the Corporation for the fiscal years ended March 31, 2025 and March 31, 2024:
| Fee Category | Fiscal Year Ended March 31, 2025 | Fiscal Year Ended March 31, 2024 | ||||
| Audit Fees | $ | 87,500 | $ | 80,500 | ||
| Audit-Related Fees | $ | 120,000 | $ | 123,000 | ||
| Tax Fees | $ | 0 | $ | 0 | ||
| All Other Fees | $ | 0 | $ | 0 | ||
| Total | $ | 207,500 | $ | 203,500 |
For purposes of the foregoing table:
- Audit Fees consist of fees billed for professional services rendered for the audit of the Corporation's annual consolidated financial statements and the review of interim financial statements and services that are normally provided in connection with statutory and regulatory filings or engagements.
- Audit-Related Fees consist of fees billed for assurance and related services that are reasonably related to the performance of the audit or review of the Corporation's financial statements and are not reported under Audit Fees.
- Tax Fees consist of fees billed for professional services for tax compliance, tax advice and tax planning.
- All Other Fees consist of fees billed for products and services other than those described above.
Election of Directors
The articles of incorporation of the Corporation provide that the Board shall consist of a minimum of three and a maximum of ten directors. The directors have determined that there will be five persons elected to the Board at the Meeting.
Management proposes that each of the persons named below be nominated at the Meeting for re-election or election, as the case may be, as directors of the Corporation to serve, until the next annual meeting of Shareholders or until his or her successor is elected or appointed. Management does not contemplate that any of the nominees will be unable to serve as a director. However, if a nominee should be unable to so serve for any reason prior to the Meeting, the persons named in the enclosed form of proxy reserve the right to vote for another nominee in their discretion. Common Shares represented by proxies in favor of management nominees will be voted FOR the election of all of the nominees whose names are set forth below, unless a Shareholder has specified in his proxy that his Common Shares are to be withheld from voting on the election of directors.
The following table and the notes below state the names of all persons to be nominated for election as directors, all other positions or offices with the Corporation now held by them, their principal occupations of employment for the previous five years, the year in which they became directors for the Corporation, their ages. As of the date hereof, none of the nominees beneficially own any Common Shares.
Common Shares represented by proxies in favor of the management nominees will be voted FOR the appointment of each of the nominees as a director of the Corporation, unless a Shareholder has specified in his proxy that his Common Shares are to be withheld from voting for any or all of the nominees.
| Name, Province, Country of Residence & Position(s) | Principal Occupation Business or Employment for Last Five Years | Date Elected or Appointed as Director | Shares Beneficially Owned or Controlled | |||
| Jody Aufrichtig (age 51), Cape Town, South Africa Chairman of the Board and Chief Executive Officer | Has served as Chairman of the Board and Strategic Business Development Officer of the Corporation since January 25, 2024. Effective October 15, 2025 Jody assumed the position of Chief Executive Officer. Previously Managing Director of Canopy Growth Africa and founder of multiple award -winning businesses. The Board believes Mr. Aufrichtig is qualified to serve as a director because of his public -company leadership (including as Chairman), chartered accountant/finance background, and extensive strategic and transactional experience (including entrepreneurship, private equity, and M&A) supporting the Company's growth and capital markets objectives in the biopharmaceutical and psychedelics markets. | January 25, 2024 (Director); October 15, 2025 (CEO) | 1,106 | |||
| Marc Balkin (age 52), Cape Town South Africa Director(1)(2)(3)(5)(6) | Has served as a director of the Corporation since January 25, 2024. Previously served as Chief Executive Officer and as a director of Newcourt Acquisition Corp from March 2021 until January 25, 2024. He is the founder of Balkin and Co., an advisory firm, since 2015 and currently serves as a partner at DiGame, a growth fund focused on Africa and the Middle East. The Board believes Mr. Balkin is qualified to serve as a director because of his public -company /SPAC leadership experience, deep M&A, investment and private equity advisory background, and legal/finance markets expertise, including significant board and investment committee work, which the Board believes is directly relevant to the Company's financing, strategic transactions, and governance needs. | January 25, 2024 | 324 |
| Name, Province, Country of Residence & Position(s) | Principal Occupation Business or Employment for Last Five Years | Date Elected or Appointed as Director | Shares Beneficially Owned or Controlled | |||
| Dr. Seth Feuerstein (age 52), Connecticut, USA Director(1)(3)(5) | Has served as a director of the Corporation since January 25, 2024 and as Founder and CEO of Oui Therapeutics, Inc. since 2019. Dr. Feuerstein also serves as a senior advisor/Highly Qualified Expert for the U.S. Department of Defense and as an Executive Director of the Center for Digital Health, Innovation, and excellence at Yale University. Dr. Feuerstein has also served as the Faculty Advisory for Innovation in Healthcare at Yale School of Medicine since 2004. The Board believes Dr. Feuerstein is qualified to serve as a director because of his clinical and healthcare innovation expertise (including leadership roles at Yale and in digital health), combined with biotechnology and psychiatric medicine experience and public -sector advisory work (including for the U.S. Department of Defense), which the Board believes strengthens oversight of the Company's R&D, clinical strategy, and healthcare commercialization priorities. | January 25, 2024 | 116 | |||
| Graham Mark Patrick (age 44)(1)(3)(4)(5) | He was appointed as a director effective December 1, 2025. He currently provides fiduciary services at Stonehage Fleming and holds multiple board appointments in Mauritius, South Africa, the British Virgin Islands and other jurisdictions, including acting as an Executive Director on the various Stonehage Fleming Mauritius companies. Mr. Patrick commenced his career in legal practice as an attorney, conveyancer and notary in South Africa. He was the Trust and Fiduciary Inland Manager at Standard Bank Private Clients, Johannesburg before taking up a position at Nedbank Private Wealth, Johannesburg as a Fiduciary Specialist. The Board believes Mr. Patrick is qualified to serve as a director because of his cross -border legal and fiduciary governance experience, including senior leadership at a global advisory firm and board/regulatory appointments across multiple jurisdictions, which the Board believes is valuable to the Company given its international structure, compliance, and corporate governance requirements. | December 1, 2025 |
| Name, Province, Country of Residence & Position(s) | Principal Occupation Business or Employment for Last Five Years | Date Elected or Appointed as Director | Shares Beneficially Owned or Controlled | |||
| Warwick Corden -Lloyd (age 46), Cape Town South Africa Director | He has served as the Chief Financial Officer of the Company since January 25, 2024 and is a Chartered Accountant and Certified Project Manager. He has over 23 years of experience working in public accounting, consulting and listed financial services companies in the UK, US and South Africa having worked for Bank of New York Mellon, Capitec Bank and Canopy Growth Corporation. He also worked for PricewaterhouseCoopers International Limited in the US, UK and South Africa. The Board believes Mr. Corden -Lloyd is qualified to serve as a director because of his public -company leadership (including as CFO and director of PGI (PSYG: CSE)), chartered accountant/finance background, and extensive corporate governance and compliance experience. | October 30, 2025 | 568 |
(1) Audit Committee Member
(2) Audit Committee Chair and Audit Committee Financial Expert
(3) Compensation Committee Member
(4) Compensation Committee Chair
(5) Nominating and Corporate Governance Committee Member
(6) Nominating and Corporate Governance Committee Chair
Executive Officers & Directors